8:30AM Alimera Sciences receives marketing authorization in Austria for the treatment of Chronic Diabetic Macular Edema (ALIM) 2.69 : Co announced the Austrian Agency for Health and Food Safety has granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies. This marketing authorization follows the completion of the Decentralized Regulatory Procedure (DCP), in which the Medicines and Healthcare products Regulatory Agency in the United Kingdom, serving as the Reference Member State, delivered a positive outcome for ILUVIEN along with six Concerned Members States, which include Austria, France, Germany, Italy, Spain and Portugal. The Austrian authorization is the first national approval in the EU. Additional CMS marketing authorizations are expected in the coming months.
surf's up......crikey
Market Data 
Markets 
